临床研究
ENGLISH ABSTRACT
玻璃体激光消融治疗有症状玻璃体混浊有效性量化评估
黄灿凤
王林丽
宁家凤
甘润
闫晓河
陈青山
作者及单位信息
·
DOI: 10.3760/cma.j.cn115989-20240122-00024
Quantitative evaluation of the effectiveness of yttrium aluminum garnet laser vitreolysis for symptomatic vitreous opacities
Huang Canfeng
Wang Linli
Ning Jiafeng
Gan Run
Yan Xiaohe
Chen Qingshan
Authors Info & Affiliations
Huang Canfeng
Ocular Fundus Department, Shenzhen Eye Hospital Affiliated to Jinan University, Shenzhen 518140, China
Wang Linli
Ocular Fundus Department, Shenzhen Eye Hospital Affiliated to Jinan University, Shenzhen 518140, China
Ning Jiafeng
Ocular Fundus Department, Shenzhen Eye Hospital Affiliated to Jinan University, Shenzhen 518140, China
Gan Run
Ocular Fundus Department, Shenzhen Eye Hospital Affiliated to Jinan University, Shenzhen 518140, China
Yan Xiaohe
Ocular Fundus Department, Shenzhen Eye Hospital Affiliated to Jinan University, Shenzhen 518140, China
Chen Qingshan
Ocular Fundus Department, Shenzhen Eye Hospital Affiliated to Jinan University, Shenzhen 518140, China
·
DOI: 10.3760/cma.j.cn115989-20240122-00024
83
14
0
0
0
0
PDF下载
APP内阅读
摘要

目的评估掺钕钇铝石榴石(Nd∶YAG)玻璃体激光消融治疗有症状玻璃体混浊的有效性。

方法采用系列病例观察研究,纳入2021年6月至2022年9月于深圳市眼科医院确诊的生理性玻璃体混浊并使用Nd∶YAG玻璃体激光消融治疗者44例44眼。治疗前及末次治疗后2个月,采用标准对数视力表测量患者最佳矫正视力(BCVA),采用共焦激光扫描系统的玻璃体红外照相测量患眼治疗前后玻璃体混浊物面积,采用双通道视觉质量分析仪(OQAS-Ⅱ)测量治疗前后的客观散射指数(OSI)值,记录随访期间并发症发生情况。统计比较各指标差异,并采用简单线性回归模型分析混浊物面积与OSI的关系。

结果Nd∶YAG激光消融治疗前后BCVA比较差异无统计学意义( t=-0.478, P=0.635)。激光消融治疗前混浊物面积为(3.043±1.942)mm 2,明显大于治疗后的(1.074±0.735)mm 2,差异有统计学意义( t=0.769, P<0.001)。激光消融治疗前OSI值为1.976±0.975,明显高于治疗后的1.560±0.796,差异有统计学意义( t=0.730, P<0.001)。线性回归分析结果显示,OSI值=1.45+0.16×玻璃体混浊物面积( F=5.681, P=0.020)。治疗后2个月未见视力下降及眼压升高者,未见外伤性白内障、视网膜损伤及裂孔发生。

结论OQAS Ⅱ系统的OSI值及玻璃体混浊物面积可作为客观评估Nd∶YAG玻璃体激光消融治疗有效性的量化评价指标。

Nd-YAG激光;客观散射指数;玻璃体混浊;激光消融;玻璃体红外照相
ABSTRACT

ObjectiveTo evaluate the effectiveness of yttrium aluminum garnet (Nd∶YAG) laser vitreolysis in the treatment of symptomatic vitreous opacity.

MethodsAn observational case series study was performed.Forty-four eyes of 44 patients diagnosed as physiological vitreous opacity in Shenzhen Eye Hospital from June 2021 to September 2022 and treated with Nd∶YAG laser vitreolysis were enrolled.Before treatment and 2 months after last treatment, best corrected visual acuity (BCVA) evaluated with standard logarithmic visual acuity chart, floater areas calculated through infrared fundus photography, and objective scattering index (OSI) obtained by the Optical Quality Analysis System (OQAS) were recorded.The occurrence of complications during the follow-up period was recorded.The differences in each indicator were compared, and a simple linear regression model was used to analyze the relationship between floater area and OSI.This study adhered to the Declaration of Helsinki and was approved by the Medical Ethics Committee of Shenzhen Eye Hospital (No.2021-6-3).Patients were informed of the study methods and purposes.Written informed consent was obtained from each subject.

ResultsThere was no significant difference in BCVA before and after Nd∶YAG laser vitreolysis ( t=-0.478, P=0.635).The floater area before laser treatment was (3.043±1.942)mm 2, which was significantly larger than (1.074±0.735)mm 2 after laser treatment ( t=0.769, P<0.001).The OSI before laser treatment was 1.976±0.975, which was significantly greater than 1.560±0.796 after laser treatment ( t=0.730, P<0.001).The results of linear regression analysis showed that the OSI=1.45+ 0.16× floater area ( F=5.681, P=0.020).No patient had visual acuity loss or intraocular pressure increase and no traumatic cataract or retinal damage occurred.

ConclusionsAfter laser treatment, the floater area decreased, the OSI decreased, and the visual quality of patients improved.The OSI from OQAS Ⅱ and floater area can be used as quantitative evaluation indicators to objectively evaluate the effectiveness of Nd∶YAG laser vitreolysis.

Nd-YAG laser;Objective scattering index;Vitreous opacity;Vitreolysis;Vitreous infrared fundus photography
Chen Qingshan, Email: mocdef.aabnis7691sqc
引用本文

黄灿凤,王林丽,宁家凤,等. 玻璃体激光消融治疗有症状玻璃体混浊有效性量化评估[J]. 中华实验眼科杂志,2025,43(01):47-51.

DOI:10.3760/cma.j.cn115989-20240122-00024

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
生理性玻璃体混浊通常与年龄相关,其主要原因是随着年龄的增长,出现玻璃体后脱离,诱导视盘周围脱落的胶原纤维形成环状膜样物,即Weiss环,可能会导致视网膜受到牵拉或刺激,从而引起玻璃体混浊;另一个原因是近视性玻璃体病变可诱导玻璃体液化,胶原析出并形成漂浮物,也会导致玻璃体混浊,临床表现为"飞蚊症" [ 1 ]。近年来,随着电子产品的广泛应用,中高度近视人群明显增多,飞蚊症的患病率也明显升高 [ 2 ]。有研究表明,飞蚊症可影响视觉质量,造成部分患者出现抑郁、焦虑等身心健康问题 [ 3 ]。既往治疗有症状玻璃体混浊的手段包括口服碘制剂及中药,但效果不明确;少数患者采取微创玻璃体切割术,但手术风险大、费用高,且属于超适应证治疗。掺钕钇铝石榴石(neodymium-doped yttrium aluminum garnet laser,Nd∶YAG)玻璃体激光消融治疗已被证实可治疗有症状的玻璃体Weiss环及较严重的玻璃体混浊,改善视觉功能,提高患者生活质量 [ 4 , 5 , 6 ]。但激光消融治疗效果的评价多采用主观评分法和B型超声扫描定性检查 [ 7 , 8 , 9 , 10 ]。有研究采用ImageJ图像处理软件对红外眼底图像中玻璃体混浊物面积进行量化分析 [ 5 ],但该方法较为复杂。客观眼内散射指数(objective scatter index,OSI)可定量测量眼内散射。OSI值越高,眼内散射越严重,可能会影响视觉质量,导致视力下降、对比敏感度降低等。目前未见关于OSI应用于玻璃体混浊激光消融治疗的报道。本研究拟利用双通道视觉质量分析仪(Optical Quality Analysis System,OQAS)-Ⅱ测得的OSI和玻璃体红外照相提供的客观数据,探讨Nd∶YAG玻璃体激光消融治疗有症状玻璃体混浊的有效性。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Milston R , Madigan MC , Sebag J Vitreous floaters:etiology,diagnostics,and management[J]. Surv Ophthalmol 201661(2)∶211-227. DOI: 10.1016/j.survophthal.2015.11.008 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Webb BF , Webb JR , Schroeder MC ,et al. Prevalence of vitreous floaters in a community sample of smartphone users[J]. Int J Ophthalmol 20136(3)∶402-405. DOI: 10.3980/j.issn.2222-3959.2013.03.27 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Kim YK , Moon SY , Yim KM ,et al. Psychological distress in patients with symptomatic vitreous floaters[J/OL]. J Ophthalmol 201720173191576[2024-06-12]. http://www.ncbi.nlm.nih.gov/pubmed/29375909. DOI: 10.1155/2017/3191576 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Singh IP . Modern vitreolysis-YAG laser treatment now a real solution for the treatment of symptomatic floaters[J]. Surv Ophthalmol 202065(5)∶581-588. DOI: 10.1016/j.survophthal.2020.02.006 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Katsanos A , Tsaldari N , Gorgoli K ,et al. Safety and efficacy of YAG laser vitreolysis for the treatment of vitreous floaters:an overview[J]. Adv Ther 202037(4)∶1319-1327. DOI: 10.1007/s12325-020-01261-w .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Brasse K , Schmitz-Valckenberg S , Jünemann A ,et al. YAG laser vitreolysis for treatment of symptomatic vitreous opacities[J]. Ophthalmologe 2019116(1)∶73-84. DOI: 10.1007/s00347-018-0782-1 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Shah CP , Heier JS . YAG laser vitreolysis vs sham YAG vitreolysis for symptomatic vitreous floaters:a randomized clinical trial[J]. JAMA Ophthalmol 2017135(9)∶918-923. DOI: 10.1001/jamaophthalmol.2017.2388 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Sun X , Tian J , Wang J ,et al. Nd:YAG laser vitreolysis for symptomatic vitreous floaters:application of infrared fundus photography in assessing the treatment efficacy[J/OL]. J Ophthalmol 201920198956952[2024-06-12]. http://www.ncbi.nlm.nih.gov/pubmed/30809388. DOI: 10.1155/2019/8956952 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Lin T , Li T , Zhang X ,et al. The efficacy and safety of YAG laser vitreolysis for symptomatic vitreous floaters of complete PVD or non-PVD[J]. Ophthalmol Ther 202211(1)∶201-214. DOI: 10.1007/s40123-021-00422-6 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Souza CE , Lima LH , Nascimento H ,et al. Objective assessment of YAG laser vitreolysis in patients with symptomatic vitreous floaters[J/OL]. Int J Retina Vitreous 202061[2024-06-12]. http://www.ncbi.nlm.nih.gov/pubmed/31988795. DOI: 10.1186/s40942-019-0205-8 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Delaney YM , Oyinloye A , Benjamin L Nd:YAG vitreolysis and pars plana vitrectomy:surgical treatment for vitreous floaters[J]. Eye (Lond) 200216(1)∶21-26. DOI: 10.1038/sj.eye.6700026 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Shaimova VA , Shaimov TB , Shaimov RB ,et al. Evaluation of YAG-laser vitreolysis effectiveness based on quantitative characterization of vitreous floaters[J]. Vestn Oftalmol 2018134(1)∶56-62. DOI: 10.17116/oftalma2018134156-62 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Jonathan M , Wa CA , Yee KMP ,et al. Ultrasound-based quantification of vitreous floaters correlates with contrast sensitivity and quality of life [J]. Invest Ophthalmol Vis Sci 201556(3)∶1611-1617. DOI: 10.1167/iovs.14-15414 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Lim JI . YAG Laser vitreolysis-is it as clear as it seems?[J]. JAMA Ophthalmol 2017135(9)∶924-925. DOI: 10.1001/jamaophthalmol.2017.1683 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Koo EH , Haddock LJ , Bhardwaj N ,et al. Cataracts induced by neodymium-yttrium-aluminium-garnet laser lysis of vitreous floaters[J]. Br J Ophthalmol 2017101(6)∶709-711. DOI: 10.1136/bjophthalmol-2016-309005 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Cowan LA , Khine KT , Chopra V ,et al. Refractory open-angle glaucoma after neodymium-yttrium-aluminum-garnet laser lysis of vitreous floaters[J]. Am J Ophthalmol 2015159(1)∶138-143. DOI: 10.1016/j.ajo.2014.10.006 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Nunes GM , Ludwig GD , Gemelli H ,et al. Long-term evaluation of the efficacy and safety of Nd:YAG laser vitreolysis for symptomatic vitreous foaters[J/OL]. Arq Bras Oftalmol 202287(2)∶0395[2024-06-16]. http://www.ncbi.nlm.nih.gov/pubmed/36169439. DOI: 10.5935/0004-2749.2021-0395 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Yin Y , Lu Y , Xiang A ,et al. Comparison of the optical quality after SMILE and FS-LASIK for high myopia by OQAS and iTrace analyzer:a one-year retrospective study[J/OL]. BMC Ophthalmol 202121(1)∶292[2024-06-16]. http://www.ncbi.nlm.nih.gov/pubmed/34340669. DOI: 10.1186/s12886-021-02048-5 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Liu L , Wang Y , Liu J ,et al. Retinal-image quality and contrast sensitivity function in eyes with epiretinal membrane:a cross-sectional observational clinical study[J/OL]. BMC Ophthalmol 201818(1)∶290[2024-06-16]. http://www.ncbi.nlm.nih.gov/pubmed/30404600. DOI: 10.1186/s12886-018-0957-1 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Ren Z , Xu L , Fan Q ,et al. Assessment of visual quality in eyes with Forme Fruste keratoconus and mild and moderate keratoconus based on Optical Quality Analysis System Ⅱ parameters[J/OL]. J Ophthalmol 202020207505016[2024-06-16]. http://www.ncbi.nlm.nih.gov/pubmed/32280532. DOI: 10.1155/2020/7505016 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
Logean E , Dalimier E , Dainty C Measured double-pass intensity point-spread function after adaptive optics correction of ocular aberrations[J/OL]. Opt Express 200816(22)∶17348-17357[2024-06-16]. http://www.ncbi.nlm.nih.gov/pubmed/18958018. DOI: 10.1364/oe.16.017348 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Gouvea L , Waring GO 4th , Brundrett A ,et al. Objective assessment of optical quality in dry eye disease using a double-pass imaging system[J]. Clin Ophthalmol 2019131991-1996[2024-06-16]. DOI: 10.2147/OPTH.S211584 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Vandermeer G , Chamy Y , Pisella PJ . Comparison of objective optical quality measured by double-pass aberrometry in patients with moderate dry eye:normal saline vs.artificial tears:a pilot study[J/OL]. J Fr Ophtalmol 201841(2)∶e51-e57[2024-06-16]. http://www.ncbi.nlm.nih.gov/pubmed/29366588. DOI: 10.1016/j.jfo.2017.12.001 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
Van Den Berg TJ , Van Rijn LJ , Michael R ,et al. Straylight effects with aging and lens extraction[J]. Am J Ophthalmol 2007144(3)∶358-363. DOI: 10.1016/j.ajo.2007.05.037 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
陈青山,Email: mocdef.aabnis7691sqc
B

黄灿凤:酝酿和设计试验、文章撰写、统计分析;王林丽:酝酿和设计试验、采集及分析/解释数据;宁家凤、甘润:采集及分析/解释数据;闫晓河:参与酝酿和设计试验;陈青山:酝酿和设计试验、实施研究、对文章的知识性内容作批评性审阅及定稿

C
所有作者均声明不存在利益冲突
D
深圳市医学重点学科建设项目 (SZXK038)
广东省高水平临床重点专科(深圳市配套建设经费)项目 (SZGSP014)
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号